151 related articles for article (PubMed ID: 12132274)
1. [Specific cellular immunotherapy of renal cell carcinoma. Current status and prospects].
Ringhoffer M; Gschwend JE
Urologe A; 2002 May; 41(3):249-57. PubMed ID: 12132274
[TBL] [Abstract][Full Text] [Related]
2. Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses.
Zhou J; Weng D; Zhou F; Pan K; Song H; Wang Q; Wang H; Wang H; Li Y; Huang L; Zhang H; Huang W; Xia J
Cancer Immunol Immunother; 2009 Oct; 58(10):1587-97. PubMed ID: 19221746
[TBL] [Abstract][Full Text] [Related]
3. Antigenic targets for renal cell carcinoma immunotherapy.
Vieweg J; Jackson A
Expert Opin Biol Ther; 2004 Nov; 4(11):1791-801. PubMed ID: 15500407
[TBL] [Abstract][Full Text] [Related]
4. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
Kirner A; Mayer-Mokler A; Reinhardt C
Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?
Bedke J; Stenzl A
Expert Rev Anticancer Ther; 2013 Dec; 13(12):1399-408. PubMed ID: 24215158
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.
Avigan DE; Vasir B; George DJ; Oh WK; Atkins MB; McDermott DF; Kantoff PW; Figlin RA; Vasconcelles MJ; Xu Y; Kufe D; Bukowski RM
J Immunother; 2007 Oct; 30(7):749-61. PubMed ID: 17893567
[TBL] [Abstract][Full Text] [Related]
7. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells.
Su Z; Dannull J; Heiser A; Yancey D; Pruitt S; Madden J; Coleman D; Niedzwiecki D; Gilboa E; Vieweg J
Cancer Res; 2003 May; 63(9):2127-33. PubMed ID: 12727829
[TBL] [Abstract][Full Text] [Related]
8. Immune response induced in vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines.
Arroyo JC; Gabilondo F; Llorente L; Meraz-Ríos MA; Sánchez-Torres C
J Clin Immunol; 2004 Jan; 24(1):86-96. PubMed ID: 14997038
[TBL] [Abstract][Full Text] [Related]
9. Vaccines in renal cell carcinoma.
Kübler H; Vieweg J
Semin Oncol; 2006 Oct; 33(5):614-24. PubMed ID: 17045091
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell-based vaccination for renal cell carcinoma: challenges in clinical trials.
Wang J; Liao L; Tan J
Immunotherapy; 2012 Oct; 4(10):1031-42. PubMed ID: 23148755
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
[TBL] [Abstract][Full Text] [Related]
12. Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma.
Leonhartsberger N; Ramoner R; Falkensammer C; Rahm A; Gander H; Höltl L; Thurnher M
Cancer Immunol Immunother; 2012 Sep; 61(9):1407-13. PubMed ID: 22278360
[TBL] [Abstract][Full Text] [Related]
13. Translational mini-review series on vaccines: Dendritic cell-based vaccines in renal cancer.
Ranieri E; Gigante M; Storkus WJ; Gesualdo L
Clin Exp Immunol; 2007 Mar; 147(3):395-400. PubMed ID: 17302887
[TBL] [Abstract][Full Text] [Related]
14. Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.
Laurell A; Lönnemark M; Brekkan E; Magnusson A; Tolf A; Wallgren AC; Andersson B; Adamson L; Kiessling R; Karlsson-Parra A
J Immunother Cancer; 2017; 5():52. PubMed ID: 28642820
[TBL] [Abstract][Full Text] [Related]
15. Recent developments in renal cell cancer immunotherapy.
Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
Expert Opin Biol Ther; 2007 May; 7(5):727-37. PubMed ID: 17477809
[TBL] [Abstract][Full Text] [Related]
16. Antigen-independent immune responses after dendritic cell vaccination.
Leonhartsberger N; Ramoner R; Putz T; Gander H; Rahm A; Falkensammer C; Bartsch G; Thurnher M
Cancer Immunol Immunother; 2007 Jun; 56(6):897-903. PubMed ID: 17106716
[TBL] [Abstract][Full Text] [Related]
17. Dendritic-cell-based immunotherapy evokes potent anti-tumor immune responses in CD105+ human renal cancer stem cells.
Zhang XF; Weng DS; Pan K; Zhou ZQ; Pan QZ; Zhao JJ; Tang Y; Jiang SS; Chen CL; Li YQ; Zhang HX; Chang AE; Wicha MS; Zeng YX; Li Q; Xia JC
Mol Carcinog; 2017 Nov; 56(11):2499-2511. PubMed ID: 28621442
[TBL] [Abstract][Full Text] [Related]
18. Tumor cell-based vaccination in renal cell carcinoma: rationale. approaches, and recent clinical development.
Volk J; Sel S; Ganser A; Schöffski P
Curr Drug Targets; 2002 Oct; 3(5):401-8. PubMed ID: 12182231
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models.
Birkhäuser FD; Koya RC; Neufeld C; Rampersaud EN; Lu X; Micewicz ED; Chodon T; Atefi M; Kroeger N; Chandramouli GV; Li G; Said JW; McBride WH; Kabbinavar FF; Ribas A; Pantuck AJ; Belldegrun AS; Riss J
J Immunother; 2013 Feb; 36(2):102-11. PubMed ID: 23377663
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.
Pandha HS; John RJ; Hutchinson J; James N; Whelan M; Corbishley C; Dalgleish AG
BJU Int; 2004 Aug; 94(3):412-8. PubMed ID: 15291878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
